Compare ProShares UltraPro QQQ ETF (TQQQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraPro QQQ ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 3.8× State Street SPDR S&P Biotech ETF's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TQQQ | XBI | |
|---|---|---|
Market Cap | $38.74B | $10.11B |
Volume | 65,384,797 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $87.22 | $169.55 |
52-Week Low | $37.89 | $104.99 |
Typical Hold Time | 24 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $80.22, down 4.04% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's 3x leverage amplifies Nasdaq-100 moves, yet hidden costs like financing charges impact returns. Recent news highlights volatility risks and institutional position changes, while support sits at $78 and resistance at $83.
Outlook remains mixed: bullish technicals and AI-driven tech growth offer upside, but leverage decay and market volatility pose significant risks. Investors face amplified losses in downturns, warranting caution despite short-term momentum opportunities.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
